2,060
Views
0
CrossRef citations to date
0
Altmetric
Research Paper

Heterogeneous associations of gut microbiota with Crohn’s disease activity

ORCID Icon, ORCID Icon, , , & ORCID Icon
Article: 2292239 | Received 12 Jun 2023, Accepted 04 Dec 2023, Published online: 17 Dec 2023

References

  • Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113–14. doi:10.25122/jml-2018-0075.
  • Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474(7351):307–317. doi:10.1038/nature10209.
  • Halfvarson J, Brislawn CJ, Lamendella R, Vazquez-Baeza Y, Walters WA, Bramer LM, D’Amato M, Bonfiglio F, McDonald D, Gonzalez A, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2(5):17004. doi:10.1038/nmicrobiol.2017.4.
  • Sha S, Xu B, Wang X, Zhang Y, Wang H, Kong X, Zhu H, Wu K. The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease. Diagn Microbiol Infect Dis. 2013;75(3):245–51. doi:10.1016/j.diagmicrobio.2012.11.022.
  • Andoh A, Kobayashi T, Kuzuoka H, Tsujikawa T, Suzuki Y, Hirai F, Matsui T, Nakamura S, Matsumoto T, Fujiyama Y. Characterization of gut microbiota profiles by disease activity in patients with Crohn’s disease using data mining analysis of terminal restriction fragment length polymorphisms. Biomed Rep. 2014;2(3):370–3. doi:10.3892/br.2014.252.
  • Galazzo G, Tedjo DI, Wintjens DSJ, Savelkoul PHM, Masclee AAM, Bodelier AGL, Pierik MJ, Jonkers DMAE, Penders J. Faecal microbiota dynamics and their relation to disease course in Crohn’s disease. J Crohns Colitis. 2019;13(10):1273–82. doi:10.1093/ecco-jcc/jjz049.
  • Andoh A, Kuzuoka H, Tsujikawa T, Nakamura S, Hirai F, Suzuki Y, Matsui T, Fujiyama Y, Matsumoto T. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease. J Gastroenterol. 2012;47(12):1298–307. doi:10.1007/s00535-012-0605-0.
  • Dey N, Soergel DA, Repo S, Brenner SE. Association of gut microbiota with post-operative clinical course in Crohn’s disease. BMC Gastroenterol. 2013;13(1):131. doi:10.1186/1471-230X-13-131.
  • Gevers D, Kugathasan S, Denson LA, Vazquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song S, Yassour M, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host & Microbe. 2014;15(3):382–392. doi:10.1016/j.chom.2014.02.005.
  • Luo A, Leach ST, Barres R, Hesson LB, Grimm MC, Simar D. The microbiota and epigenetic regulation of T helper 17/regulatory T cells: in search of a balanced immune system. Front Immunol. 2017;8:417. doi:10.3389/fimmu.2017.00417.
  • Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489(7415):220–230. doi:10.1038/nature11550.
  • Vester-Andersen MK, Prosberg MV, Jess T, Andersson M, Bengtsson BG, Blixt T, Munkholm P, Bendtsen F, Vind I. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol. 2014;109(5):705–14. doi:10.1038/ajg.2014.45.
  • van Best N, Hornef MW, Savelkoul PH, Penders J. On the origin of species: factors shaping the establishment of infant’s gut microbiota. Birth Defects Res C Embryo Today. 2015;105(4):240–251. doi:10.1002/bdrc.21113.
  • Cade BS, Noon BR. A gentle introduction to quantile regression for ecologists. Front Ecol Environ. 2003;1(8):412–420. doi:10.1890/1540-9295(2003)001[0412:AGITQR]2.0.CO;2.
  • Koenker R. Quantile regression (econometric society monographs). Cambridge: Cambridge University Press; 2005. doi:10.1017/CBO9780511754098.
  • Knight CA, Ackerly DD. Variation in nuclear DNA content across environmental gradients: a quantile regression analysis. Ecol Lett. 2002;5(1):66–76. doi:10.1046/j.1461-0248.2002.00283.x.
  • Geraci M, Bottai M. Linear quantile mixed models. Stat Comput. 2014;24(3):461–479. doi:10.1007/s11222-013-9381-9.
  • Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol. 2009;587(Pt 17):4153–8. doi:10.1113/jphysiol.2009.174136.
  • Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57(1):289–300. doi:10.1111/j.2517-6161.1995.tb02031.x.
  • Pinheiro JC, Bates DM. Stat Comput. New York: Springer; 2002. p. 528. doi:10.1007/b98882.
  • Faust K, Raes J. Microbial interactions: from networks to models. Nat Rev Microbiol. 2012;10(8):538–550. doi:10.1038/nrmicro2832.
  • Scheffer M, Carpenter SR, Lenton TM, Bascompte J, Brock W, Dakos V, van de Koppel J, van de Leemput IA, Levin SA, van Nes EH, et al. Anticipating critical transitions. Sci. 2012;338(6105):344–348. doi:10.1126/science.1225244.
  • Folke C, Carpenter SR, Walker B, Scheffer M, Elmqvist T, Gunderson L, Holling CS. Regime shifts, resilience, and biodiversity in ecosystem management. Annu Rev Ecol Evol Syst. 2004;35(1):557–81. doi:10.1146/annurev.ecolsys.35.021103.105711.
  • Carpenter SR, Cole JJ, Pace ML, Batt R, Brock WA, Cline T, Coloso J, Hodgson JR, Kitchell JF, Seekell DA, et al. Early warnings of regime shifts: a whole-ecosystem experiment. Sci. 2011;332(6033):1079–1082. doi:10.1126/science.1203672.
  • Lahti L, Salojärvi J, Salonen A, Scheffer M, de Vos WM. Tipping elements in the human intestinal ecosystem. Nat Commun. 2014;5(1):4344. doi:10.1038/ncomms5344.
  • Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, Martinez X, Varela E, Sarrabayrouse G, Machiels K, et al. A microbial signature for Crohn’s disease. Gut. 2016;66(5):813–822. doi:10.1136/gutjnl-2016-313235.
  • Kolho KL, Korpela K, Jaakkola T, Pichai MV, Zoetendal EG, Salonen A, de Vos WM. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol. 2015;110(6):921–30. doi:10.1038/ajg.2015.149.
  • Cade BS, Noon BR, Flather CH. Quantile regression reveals hidden bias and uncertainty in habitat models. Ecology. 2005;86(3):786–800. doi:10.1890/04-0785.
  • Magro DO, Santos A, Guadagnini D, de Godoy FM, Silva SHM, Lemos WJF, Vitulo N, Torriani S, Pinheiro LV, Martinez CAR, et al. Remission in Crohn’s disease is accompanied by alterations in the gut microbiota and mucins production. Sci Rep. 2019;9(1):13263. doi:10.1038/s41598-019-49893-5.
  • Pisani A, Rausch P, Bang C, Ellul S, Tabone T, Marantidis Cordina C, Zahra G, Franke A, Ellul P. Dysbiosis in the gut microbiota in patients with inflammatory bowel disease during remission. Microbiol Spectr. 2022;10(3):e0061622. doi:10.1128/spectrum.00616-22.
  • Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter D, Ley RE, Bell JT, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749–756. doi:10.1136/gutjnl-2015-310861.
  • Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13(9):R79. doi:10.1186/gb-2012-13-9-r79.
  • Consortium THMP. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–214. doi:10.1038/nature11234.
  • van den Heuvel TRA, Jonkers DMAE, Jeuring SFG, Romberg-Camps MJL, Oostenbrug LE, Zeegers MP, Masclee AA, Pierik MJ. Cohort profile: the Inflammatory Bowel Disease South Limburg cohort (IBDSL). Int J Epidemiol. 2017;46(2):e7.
  • Mujagic Z, Ludidi S, Keszthelyi D, Hesselink M, Kruimel J, Lenaerts K, Hanssen NMJ, Conchillo JM, Jonkers DMAE, Masclee AAM. Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. Aliment Pharmacol Ther. 2014;40(3):288–297. doi:10.1111/apt.12829.